Browsing Tag
PARP inhibitors
4 posts
Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
IMNN-001 plus PARP inhibitors shows extended survival in ovarian cancer. Find out what this means for IMUNON Inc. and future treatment strategies.
FDA approval positions MyChoice CDx as key HRD test for ovarian cancer therapy selection
Myriad Genetics secures FDA approval for MyChoice CDx with Zejula. Discover how this reshapes oncology diagnostics and precision medicine markets.
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
Rubraca beats docetaxel in TRITON3: FDA clears early-line prostate cancer use for Tolmar
Tolmar’s Rubraca gains FDA approval for BRCA-mutated prostate cancer before chemotherapy. Explore the trial results and what it means for treatment strategy.